This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
Tempus AI Stock Jumps Post Q2 as EBITDA Breakeven Nears: Buy or Hold?
by Urmimala Biswas
Tempus AI's soaring Q2 revenues, margin gains and near-EBITDA breakeven position it as a fast-rising force in precision medicine.
IRTCNegative Net Change SOPHPositive Net Change TEMNegative Net Change
artificial-intelligence earnings-outlook earnings-report earnings-surprise healthcare medical medical-devices
Hims & Hers Stock Plunges 21.3% in 3 Months: Time to Hold or Exit?
by Debanjana Dey
HIMS records subscriber surge and revenue growth in second-quarter 2025, but rising costs strain gross margins.
TDOCNegative Net Change AMWLNegative Net Change HIMSNegative Net Change
medical medical-devices
Time to Buy Eli Lilly and Other Undervalued Healthcare Stocks?
by Ethan Feller
Eli Lilly, CorMedix and Johnson & Johnson represent a diversified mix of healthcare stocks with bullish catalysts
JNJNegative Net Change LLYNegative Net Change CRMDNegative Net Change
biotechnology medical medical-devices pharmaceuticals
After Golden Cross, Brink's (BCO)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
BCONegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Janus Henderson Group plc (JHG) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
JHGPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
ISRG's Ion Platform Procedure Grows 52%: Can This Trend Continue?
by Indrajit Bandyopadhyay
Intuitive Surgical's Ion platform saw Q2 procedures jump 52% to 35,000, expanding globally as utilization rises despite softer system placements.
SYKNegative Net Change ISRGNegative Net Change GMEDNegative Net Change
medical medical-devices
Hologic Eyes Organic Growth Rebound in 2026 on Breast Health Strength
by Moumi Mondal
HOLX targets a mid-single-digit organic growth rebound in 2026, powered by Breast Health recovery and new product innovation.
HOLXNegative Net Change MMSINegative Net Change GEHCPositive Net Change
medical medical-devices
Globus Medical Stock Up on Q2 Earnings & Revenue Beat, Margins Expand
by Zacks Equity Research
GMED posts strong Q2 with earnings and revenues, boosted by the Nevro acquisition and expanded margins.
BSXNegative Net Change GMEDNegative Net Change MEDPPositive Net Change WGSNegative Net Change
earnings medical medical-devices
SRDX Stock Up Following Q3 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
Surmodics delivers third-quarter fiscal 2025 earnings beat with narrower loss, as revenue tops estimates despite lower SurVeil DCB sales.
BSXNegative Net Change SRDXPositive Net Change WSTPositive Net Change GEHCPositive Net Change
earnings medical medical-devices
Hims & Hers Drives the Consumer-Centric Transformation in Digital Care
by Debanjana Dey
HIMS leverages its consumer-first telehealth model, AI-driven personalization and global expansion plans to outpace industry growth.
TDOCNegative Net Change HIMSNegative Net Change DOCSPositive Net Change
medical medical-devices
Reasons to Add Veeva Systems Stock to Your Portfolio for Now
by Zacks Equity Research
VEEV's strong first quarter, product innovations and strategic deals drive growth prospects despite rising costs.
BSXNegative Net Change WSTPositive Net Change VEEVNegative Net Change MEDPPositive Net Change
medical medical-devices
CAH Q4 Earnings Beat Estimates, '26 EPS View Up, Stock Falls
by Zacks Equity Research
Cardinal Health's fourth-quarter fiscal 2025 results benefit from solid Medical and Other segments' revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.
BSXNegative Net Change CAHNegative Net Change WSTPositive Net Change MEDPPositive Net Change
earnings medical medical-devices
Rapt Therapeutics (RAPT)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
RAPTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View Up
by Zacks Equity Research
Exact Sciences tops on Q2 earnings and revenue estimates and raises the 2025 outlook, but shares slide 8% after results.
BSXNegative Net Change EXASNegative Net Change MEDPPositive Net Change WGSNegative Net Change
earnings medical medical-devices
Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise
by Zacks Equity Research
PODD posts strong Q2 earnings and revenues and lifts its 2025 outlook, marking a decade of 20%+ constant-currency growth.
BSXNegative Net Change PODDNegative Net Change MEDPPositive Net Change WGSNegative Net Change
earnings medical medical-devices
ISRG's Post-Earnings Slide: Margin Worries Overshadow Growth Story
by Indrajit Bandyopadhyay
Intuitive Surgical's Q2 revenues and procedure gains look good, but tariffs, cost inflation, and margin pressure spur a post-earnings selloff.
MDTNegative Net Change ISRGNegative Net Change ZBHNegative Net Change
medical medical-devices
4 Dental Supplies Stocks Likely to Gain Amid Rising Tariff Risks
by Indrajit Bandyopadhyay
Here, we discuss four stocks from the Dental Supplies industry that are likely to generate wealth for investors amid tariff uncertainty. These are MCK, CAH, WST and COO.
MCKNegative Net Change CAHNegative Net Change COONegative Net Change WSTPositive Net Change
medical medical-devices
Bruker's Q2 Earnings Miss Estimates, Stock Tumbles, Margins Contract
by Zacks Equity Research
BRKR's Q2 profit drops sharply, revenues decrease, and weak demand leads to guidance cuts despite cost-saving plans.
BSXNegative Net Change BRKRPositive Net Change MEDPPositive Net Change WGSNegative Net Change
earnings medical medical-devices
Take the Zacks Approach to Beat the Markets: Digi Power X, RF Industries & Starbucks in Focus
by Santanu Roy
Zacks spotlights Digi Power X, RF Industries and Starbucks as standout gainers amid market volatility and economic uncertainty.
GSPositive Net Change JNJNegative Net Change SBUXPositive Net Change INTUPositive Net Change MTDPositive Net Change APAMNegative Net Change SHOPPositive Net Change NOBLNegative Net Change NTLAPositive Net Change RFILNegative Net Change FHINegative Net Change DGXXNegative Net Change
business-services computers finance internet medical medical-devices pharmaceuticals restaurants semiconductor
Inogen Stock Gains Following Q2 Earnings Beat, Revenues Up Y/Y
by Zacks Equity Research
INGN stock rises as Q2 loss narrows and revenue climbs 4% year over year, driven by strong B2B demand despite DTC and rental declines.
BSXNegative Net Change WSTPositive Net Change INGNPositive Net Change MEDPPositive Net Change
earnings medical medical-devices
PacBio Stock Up on Q2 Earnings & Revenue Beat Estimates, Margin Rises
by Zacks Equity Research
PACB stock jumps after Q2 results beat estimates, with narrow losses, rising margins, and strong global demand.
BSXNegative Net Change WSTPositive Net Change PACBPositive Net Change MEDPPositive Net Change
earnings medical medical-devices
DOCS Stock Up in Pre-Market Post Q1 Earnings Beat, Gross Margin Down
by Zacks Equity Research
Doximity beats first-quarter fiscal 2026 estimates with double-digit revenue growth and lifts its full-year forecast.
BSXNegative Net Change WSTPositive Net Change DOCSPositive Net Change GEHCPositive Net Change
earnings medical medical-devices
AMN Stock Slips Despite Q2 Earnings & Revenue Beat, Margins Down
by Zacks Equity Research
AMN Healthcare tops second-quarter 2025 earnings and revenue forecasts, but margins and segment sales face continued pressure.
BSXNegative Net Change AMNNegative Net Change WSTPositive Net Change GEHCPositive Net Change
earnings medical medical-devices
After Golden Cross, Halozyme Therapeutics (HALO)'s Technical Outlook is Bright
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
HALONegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Reddit Inc. (RDDT) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
RDDTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines